Industry News

L’Oréal To Advance Longevity Science with Tru Diagnostic

The collaboration aims to explore the connection between beauty indicators and changes in epigenomic markers, paving the way for advancements in the field of longevity.

Author Image

By: Lianna Albrizio

Associate Editor

L’Oréal is advancing longevity science with a strategic research and development partnership with Tru Diagnostic, a foremost authority in epigenomics testing.

The collaboration aims to explore the connection between beauty indicators and changes in epigenomic markers, paving the way for advancements in the field of longevity.

With over a century of combined expertise in skin and hair biology, L’Oréal says it’s uniquely positioned to leverage its extensive knowledge in beauty science. The partnership with Tru Diagnostic will facilitate a series of innovative studies designed to unlock the intricate relationship between epigenetics and beauty, ultimately leading to the development of advanced products that promote not just aesthetic appeal, but long-term skin and hair health.

Valuable Diagnostic Insight

“Partnering with Tru Diagnostic represents a significant milestone for us,” said Guive Balooch, head of open innovation and augmented beauty at L’Oréal. “By combining our deep understanding of beauty biology with Tru Diagnostic’s cutting-edge expertise in epigenomics, we are poised to lead the field of longevity biomarker discoveries that will bring new product offerings and valuable diagnostic insight to our consumers, to proactively care for their skin and hair health with the best longevity science solutions.”

Matthew Dawson, CEO of Tru Diagnostic, said epigenomics has the potential to revolutionize our understanding of beauty at a biological level.

“Together, we aim to lead the charge in integrating epigenetic science into the beauty industry, creating innovative products that truly reflect the future of beauty and longevity,” he said.

Keep Up With Our Content. Subscribe To Happi Newsletters